EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors

Ecaterina E Dumbrava, Do-Youn Oh, Min-Hee Ryu, Emiliano Calvo, Elena Garralda, Wei-Pang Chung, Li-Yuan Bai, Katerin Rojas, Ozlem Yildirim, Serena Masciari, Gu Mi, Lei Wang und 9 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014309 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Ecaterina E Dumbrava und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA eeileana@mdanderson.org Victor.Moreno@startmadrid.com. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Neoplasms, T-Lymphocytes, Antibodies, Bispecific. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of SAR443216 in participants with relapsed/refractory (R/R) HER2-expressing solid tumors.

Methods

In this multicenter, open-label, non-randomized Phase 1 study ( NCT05013554 ), SAR443216 was administered intravenously at dose levels (DLs) of 18–900 µg. Dose escalation occurred within participants using intraparticipant lead-in dosing (2-week and 3-week lead-in cohorts). The primary objective was to determine the maximum tolerated dose (MTD); secondary objectives included PK, immunogenicity, and preliminary clinical activity.

Results

40 participants (n≥3 at each DL) were treated with SAR443216. The median treatment duration was ~8 weeks in both 2-week and 3-week lead-in cohorts. Nearly all participants (97.5%) had at least one treatment-emergent adverse event (TEAE), of which 45% were grade ≥3. Most frequent TEAEs were cytokine release syndrome (CRS, 50%), fever (35%), alanine aminotransferase elevation (32.5%), aspartate aminotransferase elevation (27.5%), and infusion-related reactions (IRRs, 27.5%). No severe CRS, IRRs, fever, or pulmonary and cardiac toxicities were observed. Disease control rates were 34.5% in the 2-week and 36.4% in the 3-week lead-in cohorts. Average duration of disease stabilization was 10.48 weeks. Median follow-up time was 3.43 weeks. No objective responses were observed. The MTD was not reached. Dose-dependent PK showed overall consistent PK profiles across DLs. SAR443216 induced serum proinflammatory cytokines and increased multiple T-cell activation markers in peripheral blood mononuclear cells, indicating T-cell activation and target engagement. However, no clear trend in T-cell abundance or activation was observed among tumor-infiltrating T cells or other immune cells.

Conclusion

These findings indicate that SAR443216 treatment is feasible and well tolerated in participants with R/R HER2+solid tumors. Further evaluation is warranted to fully characterize the efficacy and safety of SAR443216. Trial registration number NCT05013554 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesNeoplasmsT-LymphocytesAntibodies, BispecificCD3 ComplexHumansFemaleMiddle AgedAdultMaleAgedMaximum Tolerated Dose

Stichwörter der Autor:innen

HER2ImmunotherapySolid tumorT cellTri-specific antibodyco-stimulatory molecules

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanAntibodies, BispecificCD3 Complex

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA eeileana@mdanderson.org Victor.Moreno@startmadrid.com.
  • Seoul National University College of Medicine, Seoul, Korea.
  • Asan Medical Center, Songpa-gu, Seoul, Korea.
  • University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea.
  • START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Förderung

  • Sanofi

Zitieren

APA

Dumbrava, E. E., Oh, D. Y., Ryu, M. H., Calvo, E., Garralda, E., Chung, W. P., Bai, L. Y., Rojas, K., Yildirim, O., Masciari, S., Mi, G., Wang, L., Rotolo, F., Gailhac, S., Attieh, E., Kanlikilicer, P., Buday, B., Perez, R., Rharbaoui, F., …, & Moreno, V. (2026). Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014309

Vancouver

Dumbrava EE, Oh DY, Ryu MH, Calvo E, Garralda E, Chung WP, et al. Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014309

BibTeX
@article{Dumbrava2026,
  author = {Dumbrava, Ecaterina E and Oh, Do-Youn and Ryu, Min-Hee and Calvo, Emiliano and Garralda, Elena and Chung, Wei-Pang and Bai, Li-Yuan and Rojas, Katerin and Yildirim, Ozlem and Masciari, Serena and Mi, Gu and Wang, Lei and Rotolo, Federico and Gailhac, Sarah and Attieh, Elham and Kanlikilicer, Pinar and Buday, Barbara and Perez, Raymond and Rharbaoui, Faiza and Abbadessa, Giovanni and Moreno, Victor},
  title = {Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014309}
}
Kostenlos starten →